In silico designing of a multi-epitope vaccine against *Burkholderia pseudomallei*: reverse vaccinology and immunoinformatics

Muhammad Shahab¹, Chandni Hayat², Ramin Sikandar², Guojun Zheng¹* and Shahina Akter³*

**Abstract**

Background: *Burkholderia pseudomallei* is an infectious agent causing severe disease melioidosis resulting in pneumonia, fever, and acute septicemia in humans. *B. pseudomallei* show resistance to drugs. No such FDA-approved vaccine is available against *B. pseudomallei*, and treatment is limited to therapy. Therefore, the scientific study was designed to develop a vaccine for *B. pseudomallei*. The protein sequence of *B. pseudomallei* was retrieved from NCBI. B-cell and T-cell epitopes were identified and further screened for allergenicity, antigenicity docking, and simulation.

Results: Here, in this study, in silico approach was applied to design a multi-epitope subunit vaccine peptide consisting of linear B-cell and T-cell epitopes of proteins considered to be potential novel vaccine candidates. Peptide epitopes were joined by adjuvant and EAAAK, CPGPG, and AAY linkers. This constructed vaccine was subjected to in silico immune simulations by C-ImmSim. The protein construct was cloned into PET28a (+) vector for expression study in *Escherichia coli* using SnapGene.

Conclusion: The designed multi-epitope vaccine was analyzed for its physicochemical, structural, and immunological characteristics, and it was found to be antigenic, soluble, stable, nonallergenic, and have a high affinity to its target receptor. The immune simulation studies were carried out on the C-ImmSim showing increased production of cellular and humoral responses indicating that the constructed vaccine proved effective and able to provoke humoral and cell-mediated response immune responses. In silico study could be a breakthrough in designing effective vaccines to eradicate *B. pseudomallei* globally.

Keywords: *Burkholderia*, Epitope, Vaccine, B cell, T cell, Immunoinformatics

**Background**

*B. pseudomallei* — gram-negative bacteria, cause infectious disease melioidosis in Australia and Asia [1]. It has been discovered by Whitmore in 1911 and associated with “glander-like” disease [2]. Among melioidosis patients, 40% of mortality rates were reported in Thailand and 21% in Australia [3].

A wide range of signs including acute septicemia, pneumonia, chronic localized infection, and fever was identified; it can also damage different organs, such as the liver, lungs, kidney, spleen, skeletal muscles, and prostate glands [4]. *B. pseudomallei* is transmitted by ingestion, inhalation, and skin abrasion [5]. Patients with renal disease, thalassemia, and diabetes reported a high risk of melioidosis [6]. Healthy patients have a significantly low risk of melioidosis. The disease may be contracted by inhalation, cutaneous inoculation, or ingestion [7]. Due to different clinical symptoms and presentations with different culture-based anomalies, it is difficult to treat in clinical settings [8]. Successful drug treatment includes strict regimens of antibiotics such as meropenem and...
ceftazidime for 14 days. However, the use of co-trimoxazole works for 6 months. But *B. pseudomallei* shows resistance to several antibiotics due to which treatment may be complicated [9]. *B. pseudomallei* show intrinsic resistance towards different other drugs also like meropenem resistance against *B. ubonensis* [10], which determines the way of similar resistance in *B. pseudomallei*.

Microorganisms are cultured in conventional vaccinology and used for pathogenic identification, isolation, characterization, reinjection, and inactivation in the host to provoke immune response [11], but these old vaccine methods are expensive and time-consuming and not suitable for some pathogens such as *B. pseudomallei*. Improvement in biology systems, proteomics, genomics, and DNA sequencing represents better understanding for estimation of pathogenic organisms for vaccine design. Some methods are cost-effective and have good accuracy and can be applied to a microorganism with the best results [12–14]. Immunoinformatics approaches are used for the determination of vaccine design [15, 16]. In vaccine design, suitable protein selection is important. Protein which is virulent, highly antigenic, and non-homologous for humans can be used to increase efficacy [17].

Different vaccines on basis of epitope predictions formed pathogens in humans, such as epitope-based vaccine development against *Plasmodium vivax* (AMA-1) [18]. Recently, epitope base candidate is against *Acinetobacter baumannii* in mice [19]. B-cell epitopes prediction is against *Trypanosoma vivax* [20]. Different vaccines are developed against human pathogens such as the *Marburgvirus* [21], Ebola virus [22], Mokola Rabies virus [23], and Crimean-Congo hemorrhagic virus [24]. However, B-cell and T-cell epitopes were predicted against SARS-CoV-2 by Ziwei et al., and experimentally checked, showing top immunogenic response in mice model [25]. Keeping in mind the importance of the multi-epitope vaccine, we design a more effective, safe, and thermodynamically stable epitope base vaccine design for *B. pseudomallei* to elicit an innate and adaptive immune response. We used the immunoinformatics approach for vaccine designing, to select nonoverlapping, nonallergic, and topmost antigenic epitopes. Constructed vaccine docked with TL4, and for estimation of effectiveness and stability, simulation was performed.

**Methods**

**Retrieval of sequence**

The protocol for designing a vaccine against *B. pseudomallei* was illustrated in Fig. 1. The research was initiated by retrieving the whole proteome of *B. pseudomallei* under accession number (ABN48669) from the NCBI database (https://www.ncbi.nlm.nih.gov/). Online server ExPasy (https://web.expasy.org/ProtParm) was used to predict the secondary structure of the protein. Protein was further screened for secondary structure prediction
and disulfide bond via PSIPRED (http://bioinf.cs.ucl.ac.uk/psipred) and DIANNA (http://clavius.bc.edu/~clotelab/DiANNA).

**Predication of protein antigenicity**

Antigenicity is used to predictability of proteins that bind to immune cells and provide adaptive immune responses [26]. For triggering immune cell response, antigens interact with B cells or T cells. Antigen has a biological key term as an epitope, binding to the corresponding antibodies.

Whenever T-cell receptor and MHC combine, linear amino acid sequences (epitopes) were identified. It is essential to identify the antigenic potential for each protein and potential epitopes. The protein was subjected to the online server VaxiJen for antigenicity prediction (http://www.ddg-pharmfac.net/vaxijen/VaxiJen/VaxiJen.html) [27].

**Allergenicity predication**

The protein was scanned for allergic prediction by analyzing it in AllerTOP v. 2.0 (https://www.ddg.pharmfac.net/AllerTOP) online server. To properly evaluate the 3D structure trRosetta (https://yanglab.nankai.edu.cn/trRosetta), online server was used.

**Screening of T-cell epitopes and antigenicity prediction and population coverage**

From the IEDB database, the common fragment was utilized for analyzing highly immunogenic T-cell epitopes via the MHC-1 (http://tools.iedb.org/mhci/) and MHC-2 tool (http://tools.iedb.org/mhci2/) [28]. Again, the VaxiJen v. 2.0 online server predicts MHC-1 and MHC-2 antigenicity [29]. Nonallergic epitopes were determined via AllerTOP v. 2.0 (https://www.ddg.pharmfac.net/AllerTOP). IEDB tool (http://www.iedb.org/) is used to predict population coverage for each epitope.

**B-cell epitope prediction**

Predication of the most potent B-cell epitopes of proteins was confirmed via the IEDB tool. Based on allergenicity, pattern, and VaxiJen score, top epitopes were ranked.

**Epitope cluster analysis and vaccine construction**

CTL, HTL, and B-cell epitopes are determined by IEDB. For vaccine construction and clusters, epitopes were utilized. Each epitope is started by B-cell and T-cell epitopes. In the host, immune interaction was induced by the interaction of Toll-like receptors and adjuvants [30]. Epitopes combine by linkers EAAAK, CPGPG, and AAY are utilized to link with all MHC-1 and MHC-2 epitopes, respectively. Vaccine is shown below:

```
EAAAKHGAEEKKDEALKNDVQLGEP4SWAFDEPGG- 
GAGLNEEGRQLVGRGMRSLARERDGECCGP-GP - 
GAESHVDRIALHEHNVRLDVFLHCPEYAEHM- 
RYAREVvaluPLKLFQYGLDQTLLLAWRIFARL- 
LWNPHFSVQLLAWREIFARVEVALPFLKLWNPHE- 
SVAAYLPVLHVSTDEVFQQRNPMLFRFLHVSD- 
TDIGANFVLWKL5LQGNPKLMIANALGGYHT- 
HTYGLPYYWALGPDADHHHHHH
```

**Antigenicity, allergenicity, and vaccine construct solubility predication**

Via VaxiJen v. 2.0 server, antigenicity was determined. However, analysis of the allergenicity pattern of the vaccine was performed by server AllerTOP v. 2.0 (https://www.ddg.pharmfac.net/AllerTOP).

**Predication of physiochemical properties**

EXPaSy as an online server functionally characterizes the constructed vaccine. Isoelectric pH, hydrophobicity, instability and aliphatic index, molecular weight, in vitro and in vivo half-life, and GRAVY were predicated.

**Secondary and tertiary structure prediction**

PSIPRED 3.3 (http://bioinf.cs.ucl.ac.uk/psipred/) predicts the alpha, beta-sheet, and coil structure of vaccine constructs. SCRATCH Protein Predictors determined three-dimensional (3D) structure of proteins.

**Refinement of tertiary structure**

Using Galaxy Refine, the vaccine tertiary structure was refined to further modify its structure quality [30].

**Validation of structure**

The constructed vaccine was validated by different online servers: PROCHECK (https://servicesn.mbi.ucla.edu/PROCHECK/) and Ramachandran plot.

**Vaccine 3D structure validation**

For validation of tertiary structure, Galaxy Refine was used. If the score is more than 90, the structure is validated.

**Docking of constructed vaccine with TLR 4**

Docking was performed to predict binding conformation and interactions of vaccine construct with TLR-4 by using ClusPro software. It is a widely used docking server, depending on 6 energy functions and protein types. Interacting residues were determined by PDBsum and PDBePISA.

**Codon optimization of vaccine sequence**

Optimization of codons and reverse vaccination sequence are determined via JCat [31]. In this tool, 3
parameters were selected, containing restriction enzyme cleavage sites, Rho-independent transcription termination, and bacterial ribosome binding sites. JCat tool predicts GC content of vaccine sequence.

**Molecular dynamic simulation**
MD simulation was performed for TLR4-vaccine complex using Amber package. Different steps of minimization, gentle heating, equilibration, and production were performed.

**Result**

**Retrieval of protein sequence**
The protein sequence of *Burkholderia pseudomallei* was extracted from the NCBI database in FASTA format with ID (ABN4866).

**Physiochemical characterization**
The characterization of vaccine construct was performed on physical and chemical properties, and physiochemical properties of *Burkholderia pseudomallei* were demonstrated via ProtParam that recognize 251 amino acids along with 28,465.62 kDa molecular weight [32]. The pI value was 6.86. ProtParam determined value of computed instability index 23.91 which design protein is a stable one. Aliphatic index 94.06 determined that our protein is a stable one along with temperature assortment [33]. The C1305H1971N367O342S6 formula identified the number of sulfur (S), oxygen (O), nitrogen (N), carbon (C), and hydrogen (H). The value of GRAVY was −0.129.

**Analysis of secondary structure and engineering of disulfide vaccine construct**
The secondary structure of the vaccine sequence was predicated on employing the online server PSIPRED [34], which exhibits 43.5% helix, 35.7% beta-sheets, and 20% loops (coil) (Fig. 2). However, disulfide bonds were demonstrated, and the score was allocated by DIANNA 1.1 tool in Table 1. By using an online server TMHMM (https://services.healthtech.dtu.dk/service.php?TMHMM-2.0), transmembrane topology was created.

Surface-exposed residues were detected at 100–130, 151–180, and 220–250, whereas residues from 135–150, 1801–188, and 254–281 were found inside the transmembrane region. The core area of the *B. pseudomallei* was determined to have residues from 105–112, 130–135, 140–150, and 199–221.

*Fig. 2* Secondary structure prediction by PSIPREDV 3.3 showing 43.5% alpha helix, 35.7% beta strand, and 20% coil
Analysis of antigenicity and allergenicity
Antigenicity and allergenicity were evaluated by VaxiJen 2.0 web server and AllerTOP v. 20. Value for antigenicity along with adjuvant and without adjuvant was representing that vaccine construct was antigenic. AllerTOP calculated the score, showing that the vaccine construct was nontoxic and nonallergic.

B-cell epitopes predication
B-cell epitopes were predicted via the IEDB tool. A total of 8 numbers were selected with a 0.5 threshold value. Nontoxic, nonallergic, and antigenic epitopes were selected, and epitopes were recognized as the most effective B-cell epitopes. Ten to 50 amino acids are used to speed up the immune response; results are illustrated in Table 2. By using Kolaskar and Tongaonkar method experimentally, amino acids were predicted [35]. Analysis was performed, maximum antigenicity was 1.09, the minimum was 0.5, and the average value was 0.6. The threshold value was adjusted to 0.4, and values more than 0.4 were considered antigenic. Epitopes are used for further screening which satisfies value. The result is highlighted in Table 3.

Good surface acceptability is used for efficient B-cell epitopes. Emini surface accessibility was used for this analysis. A total of 0.6 was the threshold value, and based on the threshold, 12 epitopes were selected. The surface accessibility area ranged from 56 to 64 residues, although 0.57 was chosen as a minimum and 1.089 was chosen as a maximum. By using the IEDB tool, B-cell epitopes analysis was shown in Table 4. As a result, 12 epitopes were selected for vaccine construction.

### Table 1: Prediction of disulfide bond calculation by DIANA1.1

| Disulfide bond scores | Cysteine sequence position | Score |
|----------------------|----------------------------|-------|
|                      |                           |       |
| 6–16                 | 10                        | PKFTKCRSPER-RETFSCHWTLG | 0.01456 |
| 6–42                 | 36                        | PKFTKCRSPER-QWEKCEPDYVS | 0.01107 |
| 6–53                 | 47                        | PKFTKCRSPER-AGENSCYFNS | 0.01238 |
| 6–67                 | 61                        | PKFTKCRSPER-IWIPYCIKLTS | 0.01052 |
| 6–81                 | 75                        | PKFTKCRSPER-TVDEKCFSDVE | 0.013 |
| 16–42                | 26                        | RETFSCHWTLG-QWEKCEPDYVS | 0.01041 |
| 16–53                | 37                        | RETFSCHWTLG-AGENSCYFNS | 0.01385 |
| 16–67                | 51                        | RETFSCHWTLG-IWIPYCIKLTS | 0.01045 |
| 16–81                | 65                        | RETFSCHWTLG-TVDEKCFSDVE | 0.01069 |
| 42–53                | 11                        | QWEKCEPDYVS-AGENSCYFNS | 0.99779 |
| 42–67                | 25                        | QWEKCEPDYVS-IWIPYCIKLTS | 0.01037 |
| 42–81                | 39                        | QWEKCEPDYVS-TVDEKCFSDVE | 0.01063 |
| 53–67                | 14                        | AGENSCYFNS-IWIPYCIKLTS | 0.0104 |
| 53–81                | 28                        | AGENSCYFNS-TVDEKCFSDVE | 0.01213 |
| 67–81                | 14                        | IWIPYCIKLTS-TVDEKCFSDVE | 0.90847 |

### Table 2: A list of Bepipred linear epitopes predicted by IEDB analysis resource

| S. no. | Start | End | Peptide | Length |
|--------|-------|-----|---------|--------|
| 1       | 7     | 7   | H       | 1      |
| 2       | 11    | 19  | GAEEKDEA | 8     |
| 3       | 43    | 56  | LKNQVQLGEP5WAF | 14  |
| 4       | 87    | 88  | DE      | 2      |
| 5       | 153   | 154 | PG      | 2      |
| 6       | 305   | 328 | GGAGLNEEGRQLVRGMS-RARAERD | 24 |
| 7       | 356   | 357 | GE      | 2      |
| 8       | 360   | 360 | G       | 1      |

### Table 3: Prediction of antigenicity using the Kolaskar and Tongaonkar technique

| Start | End | Peptide | Length |
|-------|-----|---------|--------|
| 223   | 233 | AESHVDRSI | 10    |
| 28    | 36  | ALHEHNVR | 9     |
| 8     | 16  | DVFLHCPY | 9     |
| 2     | 10  | EAHIRMRYAR | 9    |
| 36    | 44  | EWALPFLK | 9     |
| 54    | 63  | FOYGLDLTQLL | 10  |
| 62    | 70  | LLAWIRIFAR | 9    |
| 49    | 57  | LLWNHFHSV | 9     |
| 61    | 70  | QLLAWIRIFAR | 10  |
| 35    | 44  | VELVALPFLK | 10   |
| 48    | 57  | VLWNHFHSV | 10    |

### Table 4: Prediction of Emini surface accessibility for the accessible region

| Start | End | Peptide | Length |
|-------|-----|---------|--------|
| 38    | 46  | AFRFLHVST | 9     |
| 26    | 34  | AKAARFRLH | 9     |
| 1     | 9   | EVLARGVPG | 9     |
| 34    | 42  | LILPLMIANA | 9    |
| 40    | 48  | ALGAKKPLPV | 9    |
| 29    | 37  | FLHVSDTEV | 9     |
| 28    | 36  | FRFHVLSDT | 9     |
| 56    | 64  | IANFVLVLD | 9     |
| 15    | 23  | LKSLQGPK  | 9     |
| 35    | 43  | LMANALGG  | 9     |
| 4     | 12  | YHHTYGLV  | 9     |
| 17    | 25  | YWSALGPD  | 9     |
**Predication of MHC-1 and MHC-2**

Estimation of MHC HLA alleles in humans on basis of IC50 value, via the SMM method. A lower IC50 value means a higher binding affinity of epitopes that interact with MHC-1 molecules. To maximize affinity for MH class-1 alleles, the total number of epitopes was designed to be fewer than 200. Allergic and toxic epitopes were removed having less than 0.4. For further screening, epitopes were selected.

A total number of 200 epitopes were selected, and based on antigenicity and non-allergenicity, 11 epitopes were selected. The MH class-1 epitopes were finalized, and HLA-B*40:01, HLA-B*44:02, HLA-A*02:01, HLA-A*02:06, HLA-A*02:03, and HLA-A*32:01 were dominant along with HLA-A*68:01 alleles, respectively. The epitopes LLWNPHFSV determined the highest antigenic score 2.2782.

Out of 55 epitopes for MHC-II, 12 were selected on basis of IC50 values. Epitopes were finalized on basis of toxicity, allergenicity, and antigenicity for further screening. The epitopes FLHVST-DEV and YHHTYGLPV are predicated as a higher binder that interacts with alleles (HLA-DQA1*05:01, DQB1*02:01, HLA-DRB1*04:01, HLA-DRB1*07:01, HLA-DRB1*09:01, HLA-DRB1*01:01).

**Vaccine construction**

The vaccine ensembles were created by combining epitopes; B-cell epitopes, MHC-1, and MHC-2 epitopes were used. 50S ribosomal protein was utilized as an adjuvant for vaccine construction. Adjuvant interacted with B-cell epitope via an EAAAK linker to create a specific immune response. CPGPG linkers were used on the linkage of MHC-1 and B cell. MH class-1 and MH class-2 epitopes were linked through AAY linkers. The B-cell epitopes, HLT, and CTL epitopes were used to merge to decrease vaccine size, and 6x His-tag was integrated at the C-terminus of vaccine sequence, for identification and purification of protein (Fig. 3). The resulting vaccine construct sequence has a molecular weight of 28,465.62 kDa and 251 aa sequence.

**Population coverage**

Population coverage was performed by the IEDB tool to find out whether MHC-1 and MHC-2 alleles interacted with different epitopes. MHC-1 alleles were distributed 75.5%, and MHC-II are distributed 82.82% in diverse geographic regions throughout the world. MHC-2 allele was dominant in Thailand (72%), followed by Japan, Europe, and North Africa with population coverage of 82.2, 78.5, and 83.4, respectively. The top coverage was...
estimated in closely related to South Asia and Norway with 79.31% and 84.79%, respectively. The lowest population coverage was estimated in Indonesia epitopes with 56.5% population coverage.

Prediction of the tertiary structure and validation of the vaccine

The ProSA 3D server was used to predict the 3D structure of the vaccine sequence, resulting in ten predicted structures for a given query sequence. The fifth model was taken for further investigation (Fig. 4). The ERRAT, ProSA-web, and PROCHECK services were used to validate the structure, identifying and correcting any potential mistakes in the projected tertiary structure. The ERRAT server projected the overall quality of the vaccine 3D structure, and the estimated quality score was 90.0% S. The Z-score was calculated to see if the input structure was within the range of similar-sized natural proteins. For Ramachandran analysis, the PROCHECK server computed 92.6% of the residues in the most favored areas, 6.0% in additional allowed regions, 1.4% in generously allowed regions, and 0.0% in residues in disallowed regions.

Docking of vaccine construct and TLR4

By using ClusPro 2.0, protein-protein docking was performed to find the interaction between vaccine construct and TLR4 [38]. A total number of 10 models were created. All complexes were analyzed through PyMOL. After analyzing different complexes, model 2 was designated for further investigation. Representation of different interactions was determined by PDBsum and PDBePISA online server. Results revealed (Fig. 5) hydrogen bonds had formed between ARG87-TYR244, GLU135-TYR244, ASN235-HIS263, ARG264-ASP260, ASP428-LYS146, ASP428-LYS146, GLN430-LYS146, GLN430-ARG150, GLN430-LYS146, HIS431-HIS153, ASP453-ARG150, ASP453-ARG150, SER455-ARG150, LYS477-SER143, ASP502-ARG150, SER529-ASN171, TRP550-ASN171,
and GLN578-PRO174 with distances of 2.65, 2.64, 2.64, 2.55, 2.84, 2.54, 2.56, 2.65, 2.89, 3.07, 3.23, 3.00, 2.78, 2.70, 2.72, 2.79, 2.96, and 2.81.

**Immune simulation**
C-ImmSim server was used for immune stimulation. Figure 6 indicates that our result immune response was the same as body immune response in the human body. Figure 6A represents the production of IgG and IgM antibodies. Figure 6B shows the high level of antibody production. IFN-γ score was high as shown in Fig. 6C. TH cell population is indicated in Fig. 6D.

**Codon optimization**
The reverse translation and codon optimization were identified in *Escherichia coli* to find expression in the vaccine through the JCat server. The vaccine sequence was comprised of nucleotides, and in sequence, CAI was 0.9541667941400593, and GC content was 70.2523240371846, which indicates expression was high. Main 2 restriction sites XhoI and NdeI were added. The restriction sites and vaccines were cloned with SnapGene software. The clone is represented in Fig. 7.

**Molecular dynamic simulation**
TLR4 and vaccine complex stability and residual flexibility are determined by RMSD and RMSF (Fig. 8). Complex stable is still 50 ns. In the different regions, residual flexibility fluctuated.

**Discussion**
Vaccination plays a vital role in immune system activation and also stops the attack of various pathogen-borne infectious disorders. The use of the surface antigenic epitopes is very crucial for designing an effective vaccine. Conventional vaccines designed for the different pathogens are used all over the world and are supposed to be the best way treatment of various disorders [36]. But these vaccines faced more problems in comparison with the in silico approach. The in silico subunit vaccines are nonhazardous, more stable, and are easily engineered compared with an old vaccine. Subunit vaccines are made up of highly immunogenic B cell and T cells which are the derivatives of the proteome of the specific pathogen [37]. For *B. pseudomallei*, up to date, no multi-epitope subunit vaccine is designed. In this study, immunoinformatics approaches were used for vaccine design against *B. pseudomallei*. First of all, proteome sequence was retrieved from NCBI.
Physiochemical properties, antigenicity, allergenicity, and secondary structures were predicated. MHC-1 and MHC-2 epitopes were also predicated.

Constructed protein antigenic score was 0.9480 at 0.5 thresholds indicating properties of antigenic vaccine and was nonallergic score at 0.5 default threshold showing nature of the nonallergic vaccine. However, the vaccine molecular weight was 28,465.62KDa. Our vaccine instability score was 23.91 which indicates the vaccine is a stable one. The theoretical pI value was 6.86, and the aliphatic index was 94.06, showing the vaccine was stable thermally. GRAVY score was −0.129, a value representing vaccine is hydrophobic. Secondary and 3D structures give information about protein function, protein–protein, protein–ligand interaction, and the dynamic of protein.

Vaccine secondary and 3D structures determined showing 43.5% alpha helix, 35.7% beta-strand, and 20.8% coil in the secondary structure were predicted. However, the 3D structure was validated via different tools such as PROCHECK, Galaxy Refine, and Ramachandran plot. All tools indicated our 3D structure vaccine is validated. ClusPro online servers were used to estimate the interaction between TLR-4 and constructed vaccines. Complex dynamics stability was confirmed by MD simulation.

Conclusion

Present scientific research was used to design a stable and safe epitope base vaccine against *B. pseudomallei* through an immunoinformatics approach. The study starts with retrieving *B. pseudomallei* proteome from NCBI. By using immunoinformatics tools, suitable proteins were selected for effective vaccine design. Epitopes of B cell and T cell were predicated by an online server. By using linkers and adjuvant, CTL and HTL joined for vaccine construction. Physiochemical properties, allergenicity, and antigenicity were predicated and got the stable and safe vaccine. Docking was performed to find out the interaction between TLR-4 and humans. Against infection, the present scientific
**Fig. 7** Cloning of the final vaccine where black showing vector and red showing insert.

**Fig. 8** Molecular dynamic simulation showing RMSD and RMSF of the complex.
study was designed to make a safe, highly immunogenic, and stable vaccine by using the most reliable immunoinformatics techniques. We recommend the movement of the constructed vaccine to the biological validation phase using appropriate model organisms to validate our findings.

Abbreviations
MHC: Major histocompatibility complex; AMA: Apical membrane antigen; TLR: Toll-like receptor; NCBI: National Center for Biotechnology Information; IEDB: Immune Epitope Database.

Acknowledgements
This work was supported by the State Key Laboratories of Chemical Resources Engineering, Beijing University of Chemical Technology, Beijing 100029, China. We would like to express our appreciation to the Bangladesh Council of Scientific and Industrial Research, Dhaka, Bangladesh.

Disclaimer
The submitted research article “In silico designing of a multi-epitope vaccine against Burkhholderia pseudomallei: reverse vaccinology and immunoinformatics” for publication in your journal of repute is a unique article, and so far we know nobody did it earlier.

Authors’ contributions
MS performed and conceptualized the study and manuscript writing. CH and RA performed the statistical analyses and drew the graphs. SA and GZ, overall, conceived the study and manuscript writing. CH and GZ participated in data collection and analysis.

Funding
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Availability of data and materials
NCBI database in FASTA format with ID (ABN4866)

Declarations
Ethics approval and consent to participate
This study does not include any experiments with humans or other living animal so that it does need ethical approval.

Consent for publication
Consents were taken from all the participants for this publication.

Competing interests
The authors declare that they have no competing interests.

Author details
1 State Key Laboratory of Chemical Resources Engineering, Beijing University of Chemical Technology, Beijing 100029, China. 2 Department of Biochemistry, Computational Medicinal Chemistry Laboratory, UCSS, Abdul Wali Khan University, Mardan, Pakistan. 3 Bangladesh Council of Scientific and Industrial Research, Dhaka, Bangladesh.

Received: 13 April 2022 Accepted: 14 June 2022
Published online: 11 July 2022

References
1. Brett PJ, Woods DE (2000) Pathogenesis of and immunity to melioidosis. Act Trop 74(2):31–210
2. Whitmore A (1913) An account of a glanders-like disease occurring in Rangoon. Epidemiol Infect 13(1):1–34. https://doi.org/10.1017/s0022172400005234
3. Perumal SR et al (2017) Melioidosis: clinical impact and public health threat in the tropics. PLoS Negl Trop Dis 11(5):e0005478
4. Saida N et al (2015) Melioidosis as a travel-associated infection: case report and review of the literature. Travel Med Infect Dis 13(5):367–381
5. Yabuuchi E et al (1992) Proposal of Burkhholderia gen. nov., and transfer of seven species of the genus Pseudomonas homology group II to the new genus, with the type species Burkholderia cepacia (Palleroni and Holmes 1981) comb. nov. Microbiol Immunol 36(12):1251–1275
6. Cheng AC, Currie BJ (2007) Melioidosis: epidemiology, pathophysiology, and management. Clin Microbiol Rev 20(3):533–533
7. Yee K et al (1988) Melioidosis, the great mimic: report of 10 cases from Malaysia. J Trop Med Hyg 91(5):249–254
8. Doker T et al (2014) Case report: fatal Burkhholderia pseudomallei infection initially reported as a Bacillus species, Ohio, 2013. Am J Trop Med Hyg 91(4):743
9. Schweizer HP (2012) Mechanisms of antibiotic resistance in Burkholderia pseudomallei: implications for treatment of melioidosis. Future Microbiol 7(12):1389–1399
10. Price EP et al (2017) Phylogeographic, genomic, and metagenomic susceptibility analysis of Burkholderia ubonensis. PLoS Negl Trop Dis 11(9):e0005928
11. Kelly DF, Rappuoli R. Reverse vaccinology and vaccines for serogroup B Neisseria meningitidis. Adv Exp Med Biol. 2005;568:217–23. https://doi.org/10.1007//0-387-25342-4_15
12. Ahmad I et al (2020) Development of multi-epitope subunit vaccine for protection against coronavirus infections based on computational vaccinology. J Biomol Struct Dyn:1–12
13. Ali A et al (2019) Immunoinformatic and systems biology approaches to predict and validate peptide vaccines against Epstein–Barr virus (EBV). Sci Rep 9(1):1–12
14. Khan A et al (2021) Combined drug repurposing and virtual screening strategies with molecular dynamics simulation identified potent inhibitors for SARS-CoV-2 main protease (3CLpro). J Biomol Struct Dyn 39(13):4659–4670
15. Rappuoli R (2001) Reverse vaccinology, a genome-based approach to vaccine development. Vaccine 19(17–19):2688–2691
16. Khan S et al (2019) Immunoinformatics and structural vaccinology is driven prediction of a multi-epitope vaccine against Mayaro virus and validation through in-silico expression. Infect Genet Evol 73:390–400
17. Naz A et al (2015) Identification of putative vaccine candidates against Helicobacter pylori exploiting exoproteome and secretome: reverse vaccinology based approach. Infect Genet Evol 32:280–291
18. Bueno LL et al (2011) Identification of a highly antigenic linear B cell epitope within Plasmodium vivax apical membrane antigen 1 (AMA-1). PLoS One 6(6):e21289
19. Wang X et al (2011) Design and evaluation of a multi-epitope assembly peptide (MEAP) against herpes simplex virus type 2 infection in BALB/c mice. Virol J 8(1):1–10
20. Guedes RLM et al (2019) A comparative in silico linear B-cell epitope prediction and characterization for South American and African Trypanosoma vivax strains. Genomics 111(3):407–417
21. Hasan M et al (2019) Vaccinomics strategy for developing a unique multi-epitope monovalent vaccine against Marburg marburgvirus. Infect Genet Evol 70:140–157
22. Bazzan SI et al (2019) In silico designed Ebola virus T-cell multi-epitope DNA vaccine constructions are immunogenic in mice. Vaccines 7(2):34
23. Mohammed A et al (2017) Epitope-based peptide vaccine design against Mokola rabies virus glycoprotein G utilizing in silico approaches. Immune Res 13(144):2 https://www.researchgate.net/publication/321970727_Epitope-Based_Peptide_Vaccine_Design_against_Mokola_Rabies_Virus_Glycoprotein_G_Using_In_Silico_Approaches
24. Nosrat M, Behbahani M, Mohabatkar H (2019) Towards the first multi-epitope recombinant vaccine against Crimean-Congo hemorrhagic fever virus: a computer-aided vaccine design approach. J Biomed Inform 93:103160
25. Chen Z et al (2021) T and B cell epitope analysis of SARS-CoV-2 S protein-based on immunoinformatics and experimental research. J Cell Mol Med 25(2):1274–1289
26. Han C, Zhang M (2019) Genetic diversity and antigenicity analysis of Streptococcus pneumoniae pneumolysin isolated from children with pneumococcal infection. Int J Infect Dis 86:57–64
27. Zaharieva N et al (2019) VaxiJen dataset of bacterial immunogens: an update. Curr Comput Aided Drug Des 15(5):398–400
28. Vita R et al (2015) The immune epitope database (IEDB) 3.0. Nucleic Acids Res 43(D1):D405–D412
29. Bhattacharya M et al (2020) Development of epitope-based peptide vaccine against novel coronavirus 2019 (SARS-CoV-2): immunoinformatics approach. J Med Virol 92(6):618–631
30. Akhand MRN et al (2020) Genome-based evolutionary lineage of SARS-CoV-2 towards the development of the novel chimeric vaccine. Infect Genet Evol 85:104517
31. Grote A et al (2005) JCat: a novel tool to adapt codon usage of a target gene to its potential expression host. Nucleic Acids Res 33(suppl_2):W526–W531
32. Gasteiger E et al (2005) Protein identification and analysis tools on the ExPaSy server. In: The proteo proto hand, pp 571–607
33. Kyte J, Doolittle RF (1982) A simple method for displaying the hydrophobic character of a protein. J Mol Biol 157(1):105–132
34. Buchan DW et al (2013) Scalable web services for the PSIPRED Protein Analysis Workbench. Nucleic Acids Res 41(W1):W349–W357
35. Kolaskar AS, Tongaonkar PC (1990) A semi-empirical method for prediction of antigenic determinants on protein antigens. FEBS Lett 276(1-2):172–174
36. Zeb A et al (2021) Genome-wide screening of vaccine targets prioritization and reverse vaccinology aided design of peptides vaccine to enforce humoral immune response against Campylobacter jejuni. Comput Biol Med 133:104412
37. Saha S, Raghava GPS (2006) Prediction of continuous B-cell epitopes in an antigen using recurrent neural network. Proteins 65(1):40–48

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.